Professional view

ondansetron hydrochloride dihydrate: prescribing and clinical use

Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.

ondansetron hydrochloride dihydrate: clinical details

Prescribing considerations

Confirm that the indication, age group and route are supported by the chosen formulation.
Review congenital or acquired QT risk, cardiac disease, bradyarrhythmia, interacting medicines and electrolyte disturbance before treatment.
Clearance is substantially reduced in moderate or severe hepatic impairment; consult the product-specific restriction.
Use caution where bowel motility is impaired because ondansetron can further delay large-bowel transit.
Oral formulations are not supported for paediatric postoperative nausea and vomiting in the selected product information; injection is the relevant route.
After adenotonsillar surgery, antiemetic control may mask occult bleeding.

Contraindications and cautions

Concomitant apomorphine treatment
Hypersensitivity to ondansetron or a formulation excipient
Avoidance is specified for congenital long-QT syndrome
Some oral liquids are unsuitable in hereditary fructose intolerance because of sorbitol

Monitoring

Correct hypokalaemia and hypomagnesaemia before administration.
Consider ECG assessment when cardiac or interaction-related QT risk is clinically significant.
Observe for serotonin syndrome when combined with serotonergic treatments.
Monitor bowel function in patients with impaired motility or possible obstruction.
Monitor hepatic function closely in children receiving hepatotoxic chemotherapy.

Clinical pharmacology

Ondansetron is a selective 5-HT3 receptor antagonist acting peripherally on vagal pathways and centrally in vomiting-control pathways. It undergoes extensive hepatic metabolism through several cytochrome P450 enzymes; only a small proportion is excreted unchanged in urine.

Formulation and product differences

The selected film-coated tablet contains lactose, and its breakline is for ease of swallowing rather than equal division.
The selected syrup contains sorbitol, sodium benzoate and propylene glycol and is measured with the supplied spoon.
The selected oral solution is supplied with an oral syringe and contains excipients requiring consideration in hereditary fructose intolerance and neonatal care.
The injection or infusion contains sodium, requires appropriate compatibility checks and is administered intravenously or intramuscularly by trained staff.